PFIZER INC PFE
Last close
28.45
2026-09-04
Market cap
$162.16B
2026-06-28 share count
52-week range
23.58 - 29.21
Valuation FY2025 figures against the last close
P/S2.6x
P/E20.9x
P/FCF17.9x
EV/EBITDA—
Dividend yield—
Diluted EPS1.36
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $62.58B | $63.63B | $59.55B | $101.17B | $73.64B | $41.65B | $40.91B | $40.83B | $52.55B | $52.82B |
| Cost of revenue | $16.07B | $17.85B | $24.95B | $34.34B | $30.82B | $8.48B | $8.05B | $8.99B | $11.23B | $12.32B |
| Gross profit | $46.51B | $45.78B | $34.60B | $66.83B | $42.81B | $33.17B | $32.85B | $31.84B | $41.32B | $40.50B |
| SG&A | $13.79B | $14.73B | $14.77B | $13.68B | $12.70B | $11.60B | $12.73B | $12.61B | $14.80B | $14.84B |
| Interest expense | $2.67B | $3.09B | $2.21B | $1.24B | $1.29B | $1.45B | $1.57B | $1.32B | $1.27B | $1.19B |
| Pre-tax income | $7.52B | $8.02B | $1.06B | $34.73B | $24.31B | $7.04B | $11.32B | $3.59B | $12.30B | $8.35B |
| Income tax | $266.0M | $28.0M | $1.11B | $3.33B | $1.85B | $370.0M | $583.0M | $266.0M | $9.05B | $1.12B |
| Net income | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B | $9.16B | $16.03B | $11.15B | $21.31B | $7.21B |
| EPS, basic | 1.37 | 1.42 | 0.38 | 5.59 | 3.92 | 1.65 | 2.88 | 1.90 | 3.57 | 1.18 |
| EPS, diluted | 1.36 | 1.41 | 0.37 | 5.47 | 3.85 | 1.63 | 2.82 | 1.87 | 3.52 | 1.17 |
| Shares, diluted (wtd. avg.) | $5.71B | $5.70B | $5.71B | $5.73B | $5.71B | $5.63B | $5.67B | $5.98B | $6.06B | $6.16B |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.14B | $1.04B | $2.92B | $468.0M | $1.98B | $1.82B | $1.35B | $1.23B | $1.43B | $2.67B |
| Short-term investments | $9.18B | $10.88B | $4.40B | $18.74B | $22.01B | $9.71B | $6.69B | $17.69B | $18.65B | $15.26B |
| Receivables | $11.87B | $11.46B | $11.57B | $10.95B | $11.48B | $7.91B | $6.77B | $8.03B | $8.22B | $8.22B |
| Inventory | $10.65B | $10.85B | $10.19B | $8.98B | $9.06B | $8.02B | $7.07B | $7.51B | $7.58B | $6.78B |
| Total current assets | $42.90B | $50.36B | $43.33B | $51.26B | $59.69B | $35.07B | $32.80B | $49.93B | $41.14B | $38.95B |
| Property, plant and equipment | $19.32B | $18.39B | $18.94B | $16.27B | $14.88B | $13.74B | $12.97B | $13.38B | $13.87B | $13.32B |
| Goodwill | $71.26B | $68.53B | $67.78B | $51.38B | $49.21B | $49.56B | $48.18B | $42.93B | $55.95B | $54.45B |
| Other intangibles | $53.73B | $55.41B | $64.90B | $43.37B | $25.15B | $28.34B | $33.94B | $35.21B | $48.74B | $52.65B |
| Total assets | $208.16B | $213.40B | $226.50B | $197.21B | $181.48B | $154.23B | $167.59B | $159.42B | $171.80B | $171.62B |
| Accounts payable | $5.24B | $5.63B | $6.71B | $6.81B | $5.58B | $4.28B | $3.89B | $4.67B | $4.66B | $4.54B |
| Short-term debt | $3.00B | $3.75B | $2.25B | $2.56B | $1.64B | $2.00B | $1.46B | $4.78B | $3.55B | $4.22B |
| Total current liabilities | $36.98B | $42.99B | $47.79B | $42.14B | $42.67B | $25.92B | $37.30B | $31.86B | $30.43B | $31.11B |
| Long-term debt | $61.64B | $57.41B | $61.54B | $32.88B | $36.20B | $37.13B | $35.95B | $32.91B | $33.54B | $31.40B |
| Total liabilities | $121.39B | $124.90B | $137.21B | $101.29B | $104.01B | $90.76B | $104.15B | $95.66B | $100.14B | $111.78B |
| Retained earnings | $114.61B | $116.72B | $118.35B | $125.66B | $103.39B | $90.39B | $97.67B | $89.55B | $85.29B | $71.77B |
| Total equity | $86.48B | $88.20B | $89.29B | $95.92B | $77.46B | $63.47B | $63.45B | $63.76B | $71.66B | $59.84B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $11.70B | $12.74B | $8.70B | $29.27B | $32.58B | $14.40B | $12.59B | $15.83B | $16.80B | $16.19B |
| Depreciation and amortisation | $6.59B | $7.01B | $6.29B | $5.06B | $5.19B | $4.68B | $5.75B | $6.38B | $6.27B | $5.76B |
| Stock-based compensation | $799.0M | $877.0M | $525.0M | $872.0M | $1.18B | $755.0M | $687.0M | $923.0M | $840.0M | $691.0M |
| Capital expenditure | $2.63B | $2.91B | $3.91B | $3.24B | $2.71B | $2.23B | $2.05B | $1.98B | $1.96B | $1.82B |
| Investing cash flow | -$1.35B | $2.65B | -$32.28B | -$15.78B | -$22.55B | -$4.27B | -$3.94B | $4.53B | -$4.74B | -$7.79B |
| Financing cash flow | -$10.30B | -$17.14B | $26.07B | -$14.83B | -$9.82B | -$9.65B | -$8.48B | -$20.44B | -$13.35B | -$9.23B |
| Buybacks | — | $0 | $0 | $2.00B | $0 | $0 | $8.87B | $12.20B | $5.00B | $5.00B |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000078003-26-000026.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $138.42B | 35.6x | 8.9% |